Shares of Fusion Pharmaceuticals were up 39% or $1.40 afterhours at $5.02 after the company announced that it is buying the investigational new drug application for an ongoing Phase 2 clinical trial evaluating 225Ac-PSMA I&T from RadioMedix.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on FUSN:
- Fusion Pharmaceuticals to resume trading at 4:35 pm ET
- Fusion Pharmaceuticals to acquire Phase 2 program for prostate cancer candidate
- Fusion Pharmaceuticals reports progress across its pipeline of TATs
- Fusion, BWXT Medical announces actinium-225 partnership
- 2 “Strong Buy” Penny Stocks That Could Go Boom